Jacob Rotmensch to Angiogenesis Inhibitors
This is a "connection" page, showing publications Jacob Rotmensch has written about Angiogenesis Inhibitors.
Connection Strength
0.200
-
A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2014 Jun; 133(3):537-41.
Score: 0.110
-
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Jun 01; 29(16):2259-65.
Score: 0.090